Treatment Archives – Page 8 of 11 – Treatment Action Group

Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa

February 17, 2020
Dorrit Walsh

An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.

Statement from the ACT NOW:END AIDS Coalition on President Trump’s State of the Union Commitment to Eradicate AIDS

February 5, 2020
Dorrit Walsh

The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.

Sanofi Withdraws Two Patent Applications on Life-Saving Tuberculosis Prevention Drugs in Europe and in Indonesia

January 22, 2020
Dorrit Walsh

Follow up to our 12/19 statement applauding Indian activists for taking legal action to oppose two patent applications filed by Sanofi in India. This joint statement from Treatment Action Group and OTMeds urges Sanofi to deliver on its promise to withdraw in all countries where the applications were filed and are still pending.

HIV & Aging

December 17, 2019
Chad Cipiti

A resource listing of articles, reports, websites, and ongoing clinical trials related to HIV and aging.

Clinical Trials for People with Suboptimal Immune Reconstitution Despite HIV Suppression

November 16, 2019
Chad Cipiti

Some individuals who initiate antiretroviral therapy (ART) experience limited recovery of CD4 T cell numbers despite suppression of HIV viral load to undetectable levels. The most common risk factors for this type of discordant response to ART are low CD4 T cell count at the time of starting and older age.

Following Restricted FDA Approval of Descovy As PrEP, TAG Calls on Gilead to Immediately Partner with Community for Research on Vaginal Exposure

October 8, 2019
Dorrit Walsh

TAG laments that development for the latest oral HIV pre-exposure prophylaxis (PrEP) left out cisgender women and transgender men, but welcomes the accountability provided—albeit belated—by the U.S. Food and Drug Administration (FDA) to rectify this inequity.

ANEA Response to Guardian Article on Gov. Rick Scott’s Rejection of $70 Million in Federal Funding to Fight Florida’s HIV/AIDS Crisis

September 18, 2019
Dorrit Walsh

The Act Now End AIDS coalition is deeply troubled by the contents of Ben Ryan’s September 11 Guardian article “'Rick Scott had us on lockdown:' how Florida said no to $70m for HIV crisis." The article, which reflects four years of investigative journalism by Ryan with additional reporting by Noah Pransky, paints a detailed picture of how Florida’s then-governor, Rick Scott, refused Medicaid expansion and federal dollars to fight the epidemic from 2015-2017

MDR-TB Treatment Guideline Communication from NYC DOHMH

January 11, 2019
Chad Cipiti

On January 11, 2019, TB Project Co-Director Lindsay McKenna attended a half-day conference hosted by the NYC Bureau of Tuberculosis Control. The recommendations from the conference are included in the NYC Department of Health and Mental Hygiene’s press release on the event, which you can download below.

Rapid Shift From Global To National Purchase of TB Drugs Increases Risk of Stockouts and Use of Drugs of Unknown Quality

October 26, 2018
Chad Cipiti

Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.

Activists Urge National TB Programs and Treatment Providers To Discontinue Use of Harmful Injectable Agents in TB Treatment

October 25, 2018
Chad Cipiti

Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.